tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

ELVN Stock Latest News

Enliven Therapeutics: Strategic Positioning and Promising Data Justify Buy Rating
RatingsEnliven Therapeutics: Strategic Positioning and Promising Data Justify Buy Rating
7d ago
ELVN
Promising Investment Opportunity: Enliven Therapeutics’ ELVN-001 Shows Strong Potential in CML Treatment
PremiumRatings
Promising Investment Opportunity: Enliven Therapeutics’ ELVN-001 Shows Strong Potential in CML Treatment
7d ago
ELVN
Enliven being 20% down on Terns news ‘makes no sense,’ says Mizuho
PremiumThe Fly
Enliven being 20% down on Terns news ‘makes no sense,’ says Mizuho
7d ago
ELVN
TERN
Enliven Therapeutics Advances in CML Treatment with ELVN-001 Study
PremiumCompany Announcements
Enliven Therapeutics Advances in CML Treatment with ELVN-001 Study
14d ago
ELVN
Enliven Therapeutics’ ELVN-001: A Promising Phase 1 Study for Chronic Myeloid Leukemia
PremiumCompany Announcements
Enliven Therapeutics’ ELVN-001: A Promising Phase 1 Study for Chronic Myeloid Leukemia
14d ago
ELVN
Enliven, Novartis drugs poised to lead in CML markets, says Clear Street
PremiumThe FlyEnliven, Novartis drugs poised to lead in CML markets, says Clear Street
24d ago
NVS
ELVN
Enliven Therapeutics: Strong Buy Rating Backed by Promising Clinical Results and Robust Financial Position
Premium
Ratings
Enliven Therapeutics: Strong Buy Rating Backed by Promising Clinical Results and Robust Financial Position
3M ago
ELVN
Enliven Therapeutics: Strong Financial Foundation and Promising ELVN-001 Development Justify Buy Rating
Premium
Ratings
Enliven Therapeutics: Strong Financial Foundation and Promising ELVN-001 Development Justify Buy Rating
3M ago
ELVN
Enliven Therapeutics: Strong Financial Health and Promising CML Treatment Drive Buy Rating
PremiumRatings
Enliven Therapeutics: Strong Financial Health and Promising CML Treatment Drive Buy Rating
3M ago
ELVN
Enliven Therapeutics Reports Positive Trial Results and Strong Financials
PremiumCompany Announcements
Enliven Therapeutics Reports Positive Trial Results and Strong Financials
3M ago
ELVN
Enliven files automatic mixed securities shelf
PremiumThe Fly
Enliven files automatic mixed securities shelf
3M ago
ELVN
Enliven reports Q2 EPS (49c) vs. (41c) last year
PremiumThe Fly
Enliven reports Q2 EPS (49c) vs. (41c) last year
3M ago
ELVN
Enliven Therapeutics’ Promising Phase 1a/1b Study on ELVN-002 in HER2+ Cancers
PremiumCompany AnnouncementsEnliven Therapeutics’ Promising Phase 1a/1b Study on ELVN-002 in HER2+ Cancers
4M ago
ELVN
Enliven Therapeutics’ Promising CML Treatment: A Study Update
Premium
Company Announcements
Enliven Therapeutics’ Promising CML Treatment: A Study Update
4M ago
ELVN
Enliven Therapeutics’ Promising CML Study Update: What Investors Need to Know
Premium
Company Announcements
Enliven Therapeutics’ Promising CML Study Update: What Investors Need to Know
4M ago
ELVN
Enliven Therapeutics Advances CML Treatment with ELVN-001 Study
PremiumCompany Announcements
Enliven Therapeutics Advances CML Treatment with ELVN-001 Study
4M ago
ELVN
Enliven price target raised to $48 from $40 at H.C. Wainwright
PremiumThe Fly
Enliven price target raised to $48 from $40 at H.C. Wainwright
4M ago
ELVN
Enliven Therapeutics’ Promising CML Study: A Potential Game-Changer?
PremiumCompany Announcements
Enliven Therapeutics’ Promising CML Study: A Potential Game-Changer?
4M ago
ELVN
Enliven Therapeutics Advances in HER2 Mutant Lung Cancer Study
PremiumCompany Announcements
Enliven Therapeutics Advances in HER2 Mutant Lung Cancer Study
4M ago
ELVN
Enliven Therapeutics Appoints New Directors at Annual Meeting
PremiumCompany AnnouncementsEnliven Therapeutics Appoints New Directors at Annual Meeting
5M ago
8K
ELVN
Short Report: Short interest in residential solar heats up again
Premium
The Fly
Short Report: Short interest in residential solar heats up again
5M ago
DBI
GES
Enliven price target raised to $52 from $40 at Baird
Premium
The Fly
Enliven price target raised to $52 from $40 at Baird
5M ago
ELVN

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >